<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03767088</url>
  </required_header>
  <id_info>
    <org_study_id>UWittenHerdecke</org_study_id>
    <nct_id>NCT03767088</nct_id>
  </id_info>
  <brief_title>Whole-body Electromyostimulation in Inpatient Rehabilitation</brief_title>
  <acronym>GERKO</acronym>
  <official_title>Evaluation of Whole-body Electromyostimulation (WB-EMS) in the Context of Inpatient Rehabilitation of Cardiological and Orthopedic Patients by Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Frank Mooren</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut für Rehabilitationswissenschaften im VFR e.V., Norderney</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Witten/Herdecke</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on various studies, scientific evidence has proven the effectiveness of whole-body
      electromyostimulation (WB-EMS) on parameters such as increased physiological performance and
      body composition.

      As a pilot project, the aim of the study is to determine the effect of additional WB-EMS as
      part of the inpatient four-week rehabilitation of sarcopenic subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The loss of muscle mass in the age-associated process (sarcopenia) is a common indication in
      the field of orthopedic and cardiac rehabilitation, which may also be reinforced by previous
      immobilization and disuse of the muscles (atrophy of muscle). Sarcopenia is defined as 2
      standard deviations of average of the same sex in middle adult life. The present project
      focuses on the sarcopenia definition of the Foundation for the National Institutes of Health
      (FNIH). Their limits are &lt; 0.789 (men) and &lt; 0.512 (women) and are calculated by adding the
      absolute muscle mass of the extremities divided by the body mass index (BMI).

      Due to reduced muscle mass and thus limited strength / performance, the implementation of
      conventional training tools with regard to generate corresponding intensities is no longer
      possible, or in persons with additional cardiac or orthopedic restrictions heavily limited.

      In view of the existing indications, the alternative training technology whole-body
      electromyostimulation (WB-EMS) is an adequate training tool for the rehabilitation process.
      The time-saving (max 20 minutes per training session) and effective training method is
      characterized by low orthopedic and cardiac stress. Thus, WB-EMS combines both relevant
      aspects of a joint-friendly training with effects on muscle mass and functionality. Through
      the simultaneous activation of up to 10 muscle regions with corresponding, subjectively
      decidedly adjustable intensity per muscle group, up to 2,800 cm2 can be addressed.
      Synchronized to a motion video, the participants perform light physical exercises in parallel
      to the current pulses.

      The aim of the study is, to evaluate the effect of additional WB-EMS during a 4-week period
      of inpatient rehabilitation, comparing 3 groups:

        1. WB-EMS, stimulating 8 muscle groups (legs,arms, core, gluteal region)

        2. partial-WB-EMS, just stimulating the lower extremities (legs, gluteal region)

        3. control, just performing the functional, mainly eccentric motion pattern without
           stimulation
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2019</start_date>
  <completion_date type="Anticipated">March 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>prospective randomized controlled parallel group design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>muscle strength</measure>
    <time_frame>4 weeks</time_frame>
    <description>isometric grip strength (DIERs Myoline professional, DIERs International GmbH)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>muscle strength</measure>
    <time_frame>4 weeks</time_frame>
    <description>isometric leg flexion/extension (DIERs Myoline professional, DIERs International GmbH)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>muscle strength</measure>
    <time_frame>4 weeks</time_frame>
    <description>isometric arm flexion/extension (DIERs Myoline professional, DIERs International GmbH)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>muscle strength</measure>
    <time_frame>4 weeks</time_frame>
    <description>isometric back flexion/extension (DIERs Myoline professional, DIERs International GmbH)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>muscle function</measure>
    <time_frame>4 weeks</time_frame>
    <description>6-min-walking test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>muscle function</measure>
    <time_frame>4 weeks</time_frame>
    <description>chair-rising test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>muscle mass via multifrequency bioimpedance analysis</measure>
    <time_frame>4 weeks</time_frame>
    <description>via multifrequency bioimpedance analysis (BIA, Inbody770, Seoul, Korea)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body fat via multifrequency bioimpedance analysis</measure>
    <time_frame>4 weeks</time_frame>
    <description>via multifrequency bioimpedance analysis (BIA, Inbody770, Seoul, Korea)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood-sample: triglycerides</measure>
    <time_frame>4 weeks</time_frame>
    <description>blood-sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood-sample: high-density lipoprotein (HDL)</measure>
    <time_frame>4 weeks</time_frame>
    <description>blood-sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood-sample: low-density lipoprotein (LDL)</measure>
    <time_frame>4 weeks</time_frame>
    <description>blood-sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood-sample: Crea/glomerular filtration rate (GfR)</measure>
    <time_frame>4 weeks</time_frame>
    <description>blood-sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood-sample: glutamate oxaloacetate transaminase (GOT)</measure>
    <time_frame>4 weeks</time_frame>
    <description>blood-sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood-sample: glutamic pyruvic transaminase (GPT)</measure>
    <time_frame>4 weeks</time_frame>
    <description>blood-sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood-sample: gamma-glutamyl transpeptidase (GGT)</measure>
    <time_frame>4 weeks</time_frame>
    <description>blood-sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood-sample: creatine kinase (CK)</measure>
    <time_frame>4 weeks</time_frame>
    <description>blood-sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood-sample: myoglobin</measure>
    <time_frame>4 weeks</time_frame>
    <description>blood-sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood-sample: sodium</measure>
    <time_frame>4 weeks</time_frame>
    <description>blood-sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>potassium</measure>
    <time_frame>4 weeks</time_frame>
    <description>blood-sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>life quality</measure>
    <time_frame>4 weeks</time_frame>
    <description>questionnaire: Short Form 36 Health Survey (SF-36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>self-efficacy</measure>
    <time_frame>4 weeks</time_frame>
    <description>questionnaire: Allgemeine Selbstwirksamkeit Kurzskala (ASKU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>activities of daily living</measure>
    <time_frame>4 weeks</time_frame>
    <description>questionnaire: Late-Life Function &amp; Disability Instrument (LLFDI)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Sarcopenia</condition>
  <arm_group>
    <arm_group_label>WB-EMS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.5 sessions per week; in total: 6 training sessions training duration: 20 min per session stimulation of 8 muscle groups (legs, gluteal region, core, arms) while performing slight eccentric pronounced physiological movement patterns parameters: 85 Hz, 350ms, intermittent, 4 s load vs 4 s regeneration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>partial WB-EMS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.5 sessions per week; in total: 6 training sessions training duration: 20 min per session stimulation of 2 muscle groups (legs, gluteal region; lower extremities) while performing slight eccentric pronounced physiological movement patterns parameters: 85 Hz, 350ms, intermittent, 4 s load vs 4 s regeneration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>active sham comparator: 1.5 sessions per week; in total: 6 training sessions training duration: 20 min per session performing slight eccentric pronounced physiological movement patterns</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WB-EMS</intervention_name>
    <description>whole body electromyostimulation</description>
    <arm_group_label>WB-EMS</arm_group_label>
    <arm_group_label>partial WB-EMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>(synchronized) Training program without WB-EMS</intervention_name>
    <description>20 min of pronounced eccentric movement patterns</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. skeletal muscle index (SMI) &lt; 0,789 (men); &lt; 0,512 (women)

          2. A general state of good health

          3. Medically approved unrestricted sports participation as shown by diagnostic
             performance test

          4. Willingness to provide signed informed consent

        Exclusion Criteria:

          1. Post-coronary artery bypass graft (ACVB) surgery in the last 3 months

          2. Condition after pacemaker and defibrillator implantation

          3. renal insufficiency from stage 3a

          4. epilepsy

          5. feverish diseases or infectious diseases

          6. Taking medicines the affect muscle metabolism

          7. severe neurological disorders

          8. Skin injuries in the area of electrodes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marc Teschler, Dr</last_name>
    <phone>+49 2333 - 9888 480</phone>
    <email>marc.teschler@uni-wh.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bettina Begerow, Dr</last_name>
    <phone>+49 2333 - 9888 481</phone>
    <email>begerow@ifr-norderney.de</email>
  </overall_contact_backup>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 4, 2018</study_first_submitted>
  <study_first_submitted_qc>December 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2018</study_first_posted>
  <last_update_submitted>December 5, 2018</last_update_submitted>
  <last_update_submitted_qc>December 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Witten/Herdecke</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Frank Mooren</investigator_full_name>
    <investigator_title>Prof. Dr. med. (Lehrstuhl für Rehabilitationswissenschaften)</investigator_title>
  </responsible_party>
  <keyword>WB-EMS</keyword>
  <keyword>rehabilitation</keyword>
  <keyword>sarcopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

